NO20020487L - 2-Pyrazolin-5-oner - Google Patents
2-Pyrazolin-5-onerInfo
- Publication number
- NO20020487L NO20020487L NO20020487A NO20020487A NO20020487L NO 20020487 L NO20020487 L NO 20020487L NO 20020487 A NO20020487 A NO 20020487A NO 20020487 A NO20020487 A NO 20020487A NO 20020487 L NO20020487 L NO 20020487L
- Authority
- NO
- Norway
- Prior art keywords
- chemical compounds
- compounds
- pyrazoline
- ones
- angiogenesis
- Prior art date
Links
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical class O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14656399P | 1999-07-30 | 1999-07-30 | |
| PCT/US2000/020628 WO2001009121A2 (en) | 1999-07-30 | 2000-07-28 | 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20020487D0 NO20020487D0 (no) | 2002-01-30 |
| NO20020487L true NO20020487L (no) | 2002-03-12 |
Family
ID=22517965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020487A NO20020487L (no) | 1999-07-30 | 2002-01-30 | 2-Pyrazolin-5-oner |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1218373A2 (es) |
| JP (1) | JP2003506368A (es) |
| KR (1) | KR20020091829A (es) |
| CN (1) | CN1193026C (es) |
| AR (1) | AR032279A1 (es) |
| AU (1) | AU6388900A (es) |
| BG (1) | BG106392A (es) |
| BR (1) | BR0012896A (es) |
| CA (1) | CA2380644A1 (es) |
| CZ (1) | CZ2002302A3 (es) |
| HK (1) | HK1049154A1 (es) |
| HU (1) | HUP0400540A3 (es) |
| IL (1) | IL147757A0 (es) |
| MX (1) | MXPA02001088A (es) |
| NO (1) | NO20020487L (es) |
| NZ (1) | NZ516850A (es) |
| PL (1) | PL354144A1 (es) |
| SK (1) | SK1512002A3 (es) |
| TR (1) | TR200200928T2 (es) |
| WO (1) | WO2001009121A2 (es) |
| ZA (1) | ZA200200477B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| WO2003011287A1 (en) * | 2001-08-03 | 2003-02-13 | Vertex Pharmaceuticals Incorporated | Pyrazolon derivatives as inhibitors of gsk-3 |
| WO2005002574A1 (en) * | 2003-06-24 | 2005-01-13 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
| WO2005012255A1 (ja) * | 2003-08-01 | 2005-02-10 | Mitsubishi Pharma Corporation | 炎症性関節疾患の治療剤 |
| WO2005034985A1 (ja) * | 2003-10-14 | 2005-04-21 | Kringle Pharma Inc. | 知的障害の改善剤 |
| AU2004308299B2 (en) | 2003-12-19 | 2011-11-24 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
| GB0329617D0 (en) * | 2003-12-23 | 2004-01-28 | Astex Technology Ltd | Pharmaceutical compounds |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| JPWO2006129583A1 (ja) * | 2005-05-30 | 2009-01-08 | 株式会社ジーンケア研究所 | ピラゾロン誘導体 |
| JPWO2006129587A1 (ja) * | 2005-05-30 | 2009-01-08 | 株式会社ジーンケア研究所 | ピラゾロン誘導体を含有する医薬組成物 |
| US7371862B2 (en) * | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| EP1957510A1 (en) | 2005-12-09 | 2008-08-20 | F.Hoffmann-La Roche Ag | Antiviral nucleosides |
| WO2008045419A1 (en) | 2006-10-10 | 2008-04-17 | Pharmasset, Inc. | Preparation of nucleosides ribofuranosyl pyrimidines |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| MX2010000617A (es) | 2007-07-17 | 2010-05-17 | Plexxikon Inc | Compuestos y metodos para modulacion de cinasa, e indicaciones de estos. |
| KR100987557B1 (ko) * | 2008-03-18 | 2010-10-12 | 이화여자대학교 산학협력단 | 혈관 재협착 치료 또는 예방용 조성물 |
| US9145424B2 (en) | 2008-11-20 | 2015-09-29 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
| CA2744016C (en) * | 2008-11-20 | 2018-12-11 | Cambria Pharmaceuticals, Inc. | Treatment of amyotrophic lateral sclerosis |
| AU2009329872B2 (en) | 2008-12-23 | 2016-07-07 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| MA33975B1 (fr) | 2009-11-06 | 2013-02-01 | Plexxikon Inc | Composés et méthodes de modulation des kinases et leurs indications d'emploi |
| CA2794671C (en) | 2010-03-31 | 2018-05-01 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
| EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
| HUE040136T2 (hu) | 2011-02-07 | 2019-02-28 | Plexxikon Inc | Vegyületek és eljárások kináz modulációra és azok indikációi |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| WO2014017802A1 (ko) | 2012-07-23 | 2014-01-30 | 주식회사 유한양행 | 퓨란-함유 융합 고리 화합물 또는 그의 염 및 이를 포함하는 약학 조성물 |
| KR20160115996A (ko) | 2014-02-14 | 2016-10-06 | 인셉션 2 인코퍼레이티드 | 피라졸론 화합물 및 이의 용도 |
| CN105037269B (zh) * | 2015-07-10 | 2018-01-19 | 中国人民解放军第二军医大学 | 取代吡唑酮类分泌型天冬氨酸蛋白酶抑制剂及其制备方法 |
| ES2905100T3 (es) | 2017-08-15 | 2022-04-07 | Agios Pharmaceuticals Inc | Activadores de piruvato quinasa para su uso en el tratamiento de trastornos sanguíneos |
| KR102625224B1 (ko) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| CN111793032B (zh) * | 2019-04-08 | 2021-11-19 | 四川省中医药科学院 | 一类吡唑啉酮类化合物及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369310A (en) * | 1979-11-19 | 1983-01-18 | Ciba-Geigy Ltd. | Bleachable dyes |
| JPH078851B2 (ja) * | 1985-07-29 | 1995-02-01 | 鐘淵化学工業株式会社 | ３−フエニルチオメチルスチレン誘導体 |
| JPS6229570A (ja) * | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | ３，５−ジイソプロピルベンジリデン複素環式化合物 |
| JP2678822B2 (ja) * | 1990-06-04 | 1997-11-19 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
-
2000
- 2000-07-28 JP JP2001514324A patent/JP2003506368A/ja not_active Withdrawn
- 2000-07-28 KR KR1020027001343A patent/KR20020091829A/ko not_active Withdrawn
- 2000-07-28 NZ NZ516850A patent/NZ516850A/en unknown
- 2000-07-28 IL IL14775700A patent/IL147757A0/xx unknown
- 2000-07-28 CZ CZ2002302A patent/CZ2002302A3/cs unknown
- 2000-07-28 BR BR0012896-1A patent/BR0012896A/pt not_active IP Right Cessation
- 2000-07-28 EP EP00950852A patent/EP1218373A2/en not_active Withdrawn
- 2000-07-28 CA CA002380644A patent/CA2380644A1/en not_active Abandoned
- 2000-07-28 HU HU0400540A patent/HUP0400540A3/hu unknown
- 2000-07-28 HK HK02109301.3A patent/HK1049154A1/zh unknown
- 2000-07-28 WO PCT/US2000/020628 patent/WO2001009121A2/en not_active Ceased
- 2000-07-28 SK SK151-2002A patent/SK1512002A3/sk unknown
- 2000-07-28 CN CNB008136823A patent/CN1193026C/zh not_active Expired - Fee Related
- 2000-07-28 TR TR2002/00928T patent/TR200200928T2/xx unknown
- 2000-07-28 PL PL00354144A patent/PL354144A1/xx not_active Application Discontinuation
- 2000-07-28 MX MXPA02001088A patent/MXPA02001088A/es unknown
- 2000-07-28 AU AU63889/00A patent/AU6388900A/en not_active Abandoned
- 2000-07-31 AR ARP000103955A patent/AR032279A1/es unknown
-
2002
- 2002-01-18 ZA ZA200200477A patent/ZA200200477B/xx unknown
- 2002-01-30 NO NO20020487A patent/NO20020487L/no not_active Application Discontinuation
- 2002-02-06 BG BG106392A patent/BG106392A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL147757A0 (en) | 2002-08-14 |
| HUP0400540A2 (hu) | 2004-06-28 |
| ZA200200477B (en) | 2003-06-25 |
| PL354144A1 (en) | 2003-12-29 |
| AR032279A1 (es) | 2003-11-05 |
| AU6388900A (en) | 2001-02-19 |
| WO2001009121A2 (en) | 2001-02-08 |
| HUP0400540A3 (en) | 2004-09-28 |
| NO20020487D0 (no) | 2002-01-30 |
| TR200200928T2 (tr) | 2002-09-23 |
| SK1512002A3 (en) | 2002-11-06 |
| EP1218373A2 (en) | 2002-07-03 |
| CA2380644A1 (en) | 2001-02-08 |
| BG106392A (bg) | 2002-12-29 |
| JP2003506368A (ja) | 2003-02-18 |
| HK1049154A1 (zh) | 2003-05-02 |
| WO2001009121A3 (en) | 2002-05-02 |
| CN1193026C (zh) | 2005-03-16 |
| BR0012896A (pt) | 2002-06-18 |
| NZ516850A (en) | 2004-09-24 |
| CZ2002302A3 (cs) | 2002-06-12 |
| MXPA02001088A (es) | 2003-09-22 |
| KR20020091829A (ko) | 2002-12-06 |
| CN1377346A (zh) | 2002-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20020487L (no) | 2-Pyrazolin-5-oner | |
| NO20015899L (no) | Benzotiazinon- og benzoksazinonforbindelser | |
| NO20011357D0 (no) | 4-Aminopyrrolopyrimidiner som kinase-inhibitorer | |
| NO20062763L (no) | Pyrrolotriazinforbindelser som kinaseinhibitorer | |
| NO331166B1 (no) | Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene | |
| NO20052733L (no) | C-6 modifiserte indazolylpyrrolotriaziner | |
| NO962386L (no) | Heterocykliske ring-kondenserte pyrimidin-derivater | |
| BR0108452A (pt) | Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva | |
| TR200101237T2 (tr) | Antralinik asit-ve tiyoantranilik asit-N-aril amidler | |
| TR200200649T2 (tr) | Farmasötik özelliklere sahip olan yeni aminodikarboksilik asit türevleri | |
| NO20090025L (no) | Pyrrolotriazinkinaseinhibitorer | |
| NO986090L (no) | Fenylalaninderivater som integrininhibitorer | |
| NO20070295L (no) | Nye CIS-imidazoliner | |
| NO20063572L (no) | Kinazolinditosylatsalt forbindelser | |
| ATE197044T1 (de) | Sulfonamide, ihre herstellung und verwendung als heilmittel und zwischenprodukte | |
| NO980313L (no) | N-(aroyl)glysin-hydroksaminsyre-derivater og beslektete forbindelser | |
| ATE284860T1 (de) | Neue verwendung von phenylheteroalkylamin- derivaten | |
| NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer | |
| NO20071574L (no) | Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander. | |
| TR200201168T2 (tr) | CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri. | |
| NO20060114L (no) | Naftylenderivater som cytokrom P450-inhibitorer | |
| MXPA02006249A (es) | Nuevos derivados de azabiciclooctano, utiles en el tratamiento de arritmias cardiacas. | |
| NO20064576L (no) | Pyrimidin-derivater for behandling av avvikende celle vekst | |
| EA200601176A1 (ru) | 3-цианохинолиновые производные с антипролиферативной активностью | |
| KR20010051660A (en) | Catalytic domain of the human effector cell cycle checkpoint protein kinase, chk1, materials and method for identification of inhibitors thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |